Parathyroid hormone (PTH) plays an important role in maintaining the calcium, phosphate and Vitamin D level in the body. The deficiency or low production of this hormone in the body is defined as hypoparathyroidism. It is a rare endocrine disorder, and the symptoms ranges from mild tingling sensation in fingers, mouth, hands or painful muscle cramps. The two form of this disorder includes deficiency in PTH due to less secretion and PTH when unable to respond from bones and kidney. The different type of treatment includes PTH blood test, calcium blood test, ECG and CT scan. Hypoparathyroidism is considered an orphan disease by the U.S. FDA and European Commission (EU) which provides opportunity to the market players to speed up the drug development process and in turn this factor will aid to propel the market growth.
Furthermore, the prime factors attributed to the market growth of the hypoparathyroidism market are the increasing population of patients suffering from hypoparathyroidism, the rising number of neck surgeries that can result in this disorder, and the development of the medical device industry. For instance, according to the research article published in the Journal of Clinical Endocrinology and Metabolism in 2016, the prevalence of an estimated 37 per 100 000 person-years in the US suffer from hypoparathyroidism and approximately 22 per 100 000 person-years suffer in Denmark. However, unawareness among users in many underdeveloped countries is hindering the market growth of Hypoparathyroidism market.
The global hypoparathyroidism market is expected to grow at a CAGR of around 8.3% over the period of next 5 years.
The market growth hypoparathyroidism can be attributed to the key factors such as rising prevalence of hypoparathyroidism, growing demand for hormonal therapy, rising screening rate of thyroid disorders and increasing research trials and pipeline drugs focused on the efficacy and better treatment of the disease. For instance, there are approximately 47 ongoing clinical at different phase of development. Most of these clinical trials are focused on the evaluation and the efficacy of different treatment lines for hypoparathyroidism treatment, involving calcium supplements, calcitriol, and magnesium level. Approximately 37% of the clinical trials are in phase 3 or 4 stage. These factors are bolstering the demand for hypoparathyroidism and projected to increase its demand in the near future. However, instances of product recall and the adverse effects of the drugs used for the treatment is acting as a limiting factor for the market growth.
HYPOPARATHYROIDISM MARKET SEGMENTATION:
By Diagnosis Type:
- Low blood calcium levels
- Low blood PTH levels
- High blood phosphorus levels
By Mode of Treatment Type:
- Injection or subcutaneous infusion
- Surgery mode
- Recombinant human parathyroid hormones (PTH)
- Dosing & monitoring
By End User:
- Endocrinologist Specialized Clinics
- Ambulatory Surgical Centre
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
North America is projected to gain dominance in the hypoparathyroidism market. The market growth in this region can be attributed to rising number patient population suffering from hypoparathyroidism. According to a published article in Journal of Rare Disorder: Diagnosis & therapy in 2018, approximately 60 out of 115,000 individuals are detected with chronic hypoparathyroidism in the US. Majority of the cases results from anterior neck surgery, that contributes to 75% of total number of hypoparathyroidism cases. The left 25% of cases are due to non-surgical or due to rare instance, or due to genetic disorders. Thus, the increasing number of these cases in this region demands for an effective treatment regimen and further fuel the market growth of hypoparathyroidism.
Asia Pacific is anticipated to exhibit the fastest growth in the near future. This owes to various factors such as the surge in the prevalence of patient populations suffering from hypoparathyroidism, a rising number of pipeline drugs of hypoparathyroidism, and rapidly improving healthcare infrastructure. Moreover, due to the ongoing COVID-19 pandemic there has been a significant drop in treatment for hypoparathyroidism care. Furthermore, clinical trial studies have also been put on hold temporarily to reduce the rising number of coronavirus cases. However, with the presence of the COVID-19 vaccines, the burden has helped to an extent for COVID-19 and the clinical trials for hypoparathyroidism and other PTH disorders are resuming for development of drug candidates. With this factor the market is expected to recover over the forecast period and will propel in the coming years. Asia Pacific region is observed to be the fastest growing regional market for Hypoparathyroidism. This region is expected to maintain its growth rate in the near future.
FEW KEY PLAYERS IN HYPOPARATHYROIDISM MARKET:
- Shire-NPS Pharmaceuticals, Inc.
- Hoffmann-La Roche Ltd.
- EnteraBio Ltd.
- WCCT GLOBAL INC.
- Takeda Pharmaceutical Company Limited
- Novartis AG
- GlaxoSmithKline plc.
- In March 2021, BridgeBio Pharma declared positive output for its 2nd stage clinical trial of its new drug Encaleret for hypoparathyroidism treatments. With this product innovation by the company widened its product portfolio in the hypoparathyroidism market.
- In November 2018, Ascendis Pharma collaborated with VISEN Pharmaceuticals, manufacture, develop, and commercialize company’s TransCon endocrinology rare disease therapies in Greater China. This includes, Hong Kong, Macau, mainland China, and Taiwan. Such collaborations among companies in the market are anticipated to expand TransCon PTH’s and its geographic reach in Asian economies.
Get a brochure of this research study Click Here